The gut peptide BPC-157 blocked amphetamine-induced repetitive behaviors in rats and prevented the development of heightened drug sensitivity caused by haloperidol.
Dual actionBPC-157 both blocked acute amphetamine effects and prevented chronic haloperidol-induced supersensitivity
What the researchers found
BPC-157 blocked acute amphetamine-induced stereotypy and prevented haloperidol-induced dopamine supersensitivity to amphetamine, without affecting normal baseline behavior.
Why it matters
BPC-157's ability to normalize disrupted dopamine signaling without sedating effects suggests it could have potential in treating conditions involving dopamine dysregulation, such as substance abuse or movement disorders.
How the study worked
Animal study in rats. BPC-157 was administered alongside amphetamine to measure acute effects on stereotypy, and during chronic haloperidol treatment to assess prevention of dopamine receptor supersensitivity.
What this study cannot tell us
Animal study only. The exact mechanism by which BPC-157 interacts with the dopamine system was not determined. Doses and clinical translation to humans remain unknown.
How to read the evidence
Moderate evidence from a controlled animal study showing clear behavioral effects, but mechanism undefined and no human data.
When this study was published
Published in 1998. BPC-157's dopamine-related effects have been explored further in subsequent animal studies.
The bigger picture
Dopamine system disruption underlies many neurological and psychiatric conditions. A peptide that can selectively normalize dopamine signaling without suppressing normal function represents a fundamentally different approach from current medications that broadly dampen or boost dopamine.
Questions still open
- What is BPC-157's exact mechanism of action on dopamine receptors?
- Could BPC-157 help prevent tardive dyskinesia in patients taking antipsychotics?
- Does BPC-157 affect other neurotransmitter systems beyond dopamine?
Common questions
What is BPC-157?
What does this mean for people taking antipsychotics?
Read the original research
A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine.
Biological psychiatry, 43(7), 511-9
Citation
Jelovac, N; Sikirić, P; Rucman, R; Petek, M; Perović, D; Konjevoda, P; Marović, A; Seiwerth, S; Grabarević, Z; Sumajstorcić, J; Dodig, G; Perić, J. (1998). A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine.. Biological psychiatry, 43(7), 511-9.